DDInter129 DDInter1676
Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Atazanavir {u} (Compound) resembles {v} (Compound) Ritonavir
Atazanavir {u} (Compound) binds {v} (Gene) ABCB1
Atazanavir {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A Inhibitors
Atazanavir {u} (Compound) causes {v} (Side Effect) Pelvic pain
Atazanavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Abiraterone
Atazanavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Caffeine
Atazanavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Atazanavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Atazanavir {u} may lead to a major life threatening interaction when taken with {v} Venetoclax
Atazanavir {u} may lead to a major life threatening interaction when taken with {v} Methylprednisolone
Atazanavir (Compound) resembles Ritonavir (Compound)
Atazanavir (Compound) binds ABCB1 (Gene)
Atazanavir (Compound) is included by Cytochrome P450 3A Inhibitors (Pharmacologic Class)
Atazanavir (Compound) causes Pelvic pain (Side Effect)
Atazanavir may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Atazanavir may cause a minor interaction that can limit clinical effects when taken with Caffeine
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene
Atazanavir may lead to a major life threatening interaction when taken with Venetoclax
Atazanavir may lead to a major life threatening interaction when taken with Methylprednisolone